<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13470">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931565</url>
  </required_header>
  <id_info>
    <org_study_id>C1701-201</org_study_id>
    <nct_id>NCT02931565</nct_id>
  </id_info>
  <brief_title>Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type II Achalasia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-dose, Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 in Patients With Achalasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are as follows:

      In patients with primary Type II Achalasia, following a single 5-mg dose of IW-1701,

        -  To assess the safety and tolerability

        -  To determine the effects on measures of esophageal function by high-resolution
           impedance manometry (HRIM)

        -  To determine the pharmacokinetic (PK) parameters, Cmax, Tmax, and AUClast
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>Within 28 days from dosing day (Day 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Integrated Relaxation Pressure (IRP) as measured by HRIM</measure>
    <time_frame>1 day (Dosing day/ Day 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration [Cmax]</measure>
    <time_frame>Within 28 days of dosing day (Day 1)</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve during a dosing interval [AUC]</measure>
    <time_frame>Within 28 days of dosing day (Day 1)</time_frame>
    <description>Area under the plasma concentration time curve during a dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed plasma concentration [Tmax]</measure>
    <time_frame>Within 28 days of dosing day (Day 1)</time_frame>
    <description>Time of maximum observed plasma concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Achalasia</condition>
  <arm_group>
    <arm_group_label>IW-1701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 5-mg dose of IW-1701 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW-1701</intervention_name>
    <arm_group_label>IW-1701</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is a male or female between 18 and 65 years old at the Screening Visit.

          -  Patient has a diagnosis of primary Type II achalasia.

          -  Patient has no contraindications to the performance of the baseline and postdose HRIM
             procedures per Investigator discretion.

        Exclusion Criteria:

          -  Patient has had any prior esophageal, periesophageal, or gastric surgery, prior
             pneumatic dilation, or prior esophageal injection of botulinum toxin or sclerosing
             agent. (Patients with prior bougie dilation â‰¤ 2 cm will be allowed)

          -  Patients with malignant or premalignant esophageal lesions.

          -  Patient has taken any drug that can affect GI motility in the 72 hours before
             Check-in through Discharge from the clinic.

          -  Other exclusion criteria specified in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jayita Sen</last_name>
    <email>C1701-201@ironwoodpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ironwood Clinical Site</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecile Research Guttermuth, PhD</last_name>
      <phone>860-585-3838</phone>
      <email>cgutterm@bristolhospital.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ironwood Clinical Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Research Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ironwood Clinical Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina C Higginbotham, MPA</last_name>
      <phone>615-322-4643</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>February 28, 2017</lastchanged_date>
  <firstreceived_date>October 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophageal Achalasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
